Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

0.5632
+0.058211.52%
Post-market: 0.5490-0.0142-2.52%19:50 EST
Volume:1.74M
Turnover:918.82K
Market Cap:22.24M
PE:-0.29
High:0.5658
Open:0.5130
Low:0.5037
Close:0.5050
52wk High:5.14
52wk Low:0.5028
Shares:39.50M
Float Shares:30.75M
Volume Ratio:2.07
T/O Rate:5.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9154
EPS(LYR):-1.6652
ROE:-78.13%
ROA:-44.62%
PB:0.34
PE(LYR):-0.34

Loading ...

Nasdaq Warns VistaGen Therapeutics Over Minimum Bid Price Compliance

Reuters
·
15 hours ago

VistaGen Therapeutics Inc. to Report Third Quarter Results and Host Corporate Update Call

Reuters
·
Feb 04

Press Release: Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

Dow Jones
·
Feb 04

Vistagen Therapeutics (VTGN) Faces Securities Litigation Following 80% Stock Collapse [January 2026]

TIPRANKS
·
Jan 29

VistaGen Therapeutics Reports Phase 3 Fasedienol Trial Fails to Meet Primary Endpoint in Social Anxiety Disorder

Reuters
·
Dec 23, 2025

Vistagen Therapeutics Inc : William Blair Cuts to Market Perform Rating

THOMSON REUTERS
·
Dec 18, 2025

Vistagen Therapeutics Inc : Maxim Group Cuts to Hold From Buy

THOMSON REUTERS
·
Dec 18, 2025

Vistagen Therapeutics Cut to Hold From Buy by Jefferies

Dow Jones
·
Dec 18, 2025

Sector Update: Health Care Stocks Softer Wednesday Afternoon

MT Newswires Live
·
Dec 18, 2025

Vistagen Therapeutics Shares Tumble in Premarket as Anxiety Drug Test Miss Targets

Dow Jones
·
Dec 17, 2025

BRIEF-Vistagen Announces Topline Results From Palisade-3 Phase 3 Study

Reuters
·
Dec 17, 2025

VistaGen Therapeutics Reports Phase 3 Trial of Fasedienol for Social Anxiety Disorder Fails to Meet Primary Endpoint

Reuters
·
Dec 17, 2025

Vistagen Announces Topline Results From Palisade-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
Dec 17, 2025

Vistagen Therapeutics Inc - Study Did Not Show Significant Improvement in Anxiety Reduction

THOMSON REUTERS
·
Dec 17, 2025

Vistagen Therapeutics Inc - Cash Preservation Measures Expected to Provide Runway Into 2027

THOMSON REUTERS
·
Dec 17, 2025

Vistagen Therapeutics Inc - Favorable Safety Data of Fasedienol Consistent With Previous Trials

THOMSON REUTERS
·
Dec 17, 2025

NASDAQ TRADE HALT HALT NEWS PENDING AT 08:25 AM

Reuters
·
Dec 17, 2025

VistaGen Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Financial Officer Nick B. Tressler

Reuters
·
Dec 04, 2025

BRIEF-Vistagen Appoints Nick Tressler As Chief Financial Officer

Reuters
·
Dec 01, 2025

Vistagen Appoints Nick Tressler as Chief Financial Officer

THOMSON REUTERS
·
Dec 01, 2025